Survival and desferrioxamine in thalassaemia major.

@article{Modell1982SurvivalAD,
  title={Survival and desferrioxamine in thalassaemia major.},
  author={B. Modell and Elizabeth A. Letsky and David M. Flynn and Richard Peto and David J. Weatherall},
  journal={British Medical Journal (Clinical research ed.)},
  year={1982},
  volume={284},
  pages={1081 - 1084}
}
A small randomised trial and observation of all patients homozygous for beta-thalassaemia in Britain born in or before 1963 indicated that those patients who had received average weekly doses of more than 4 g of desferrioxamine over the previous few years were less likely to die in the near future than were patients of similar ages who had received less, or no, desferrioxamine. 
Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register
About 50% of UK patients with beta-thalassaemia major die before the age of 35 years, mainly because conventional iron-chelation therapy is too burdensome for full adherence. Patients require anExpand
MARROW TRANSPLANTATION FOR THALASSAEMIA
Abstract A 16-month-old boy with thalassaemia major was prepared with one dose of dimethyl busulphan, 5 mg/kg, and with cyclophosphamide, 50 mg/kg on 4 successive days, and given marrow from aExpand
Management of pregnancy in a patient with beta thalassaemia major.
TLDR
A case of a pregnant patient with beta thalassaemia major who underwent a successful caesarean section under spinal anaesthesia is reported and the multidisciplinary approach to management of beta ThalassAemia major and pregnancy is discussed. Expand
The effects of desferrioxamine iron chelation therapy in hypertransfused beta-thalassemia patients
Twenty-one patients with beta-thalassemia treated with hypertransfusion and subcutaneous Desferrioxamine (DF) chelation received annual evaluations of serum ferritin level and hepatic, endocrine, andExpand
Beta-thalassaemia--the Johannesburg experience.
TLDR
Despite adequate iron excretion as a result of subcutaneous desferrioxamine (DFO) infusions, the patients showed significant iron overload, which suggested poor compliance in the home use of DFO and was the main long-term problem in the treatment of beta-thalassaemia major. Expand
Mapping the prevalence of sickle cell and beta thalassaemia in England: estimating and validating ethnic‐specific rates
A range of estimates for sickle cell and β thalassaemia have been derived for the different ethnic groups living in the U.K., reflecting uncertainty over the true population value in certainExpand
Survival in a large cohort of Greek patients with transfusion‐dependent beta thalassaemia and mortality ratios compared to the general population
TLDR
The prognosis for transfusions and chelation therapy for transfusion‐dependent beta thalassaemia has changed from being fatal in early childhood to a chronic disorder with prolonged survival. Expand
Amenorrhea in β‐Homozygous Thalassemia Major
TLDR
A transition, from low-amplitude endogenous GnRH pulses to apulsatility of LH patterns, precedes the inability of the pituitary gonadotrope to respond to the GnRH decapeptide administered either as an acute bolus injection or in a pulsatile manner for up to 7 days. Expand
Deferoxamine-induced growth retardation in patients with thalassemia major.
TLDR
The results indicate that in patients with thalassemia major, DF administration should be initiated only after iron accumulation is established, namely, around 3 years of age, after 20 to 30 transfusions, which are usually associated with ferritin levels in the range of 800 to 1000 ng/ml. Expand
Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
TLDR
This data indicates that once patients with β-thalassaemia major experience chronic iron overload due to regular blood transfusions using iron-chelating therapies such as desferrioxamine (DFO), deferiprone (DFP) and deferasirox (DFX) monotherapy, or DFO–DFP combination therapy, should be considered for further study. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
LONG‐TERM DESFERRIOXAMINE THERAPY IN THALASSEMIA
TLDR
Clinical observations are presented under the three headings of the expectations, the findings, and improvements in the chelation scheme in the light of these findings. Expand
PREVENTION OF IRON LOADING IN TRANSFUSION-DEPENDENT THALASSÆMIA
TLDR
Iron loading in transfusion-dependent thalassaemics may be preventable by the use of an appropriate chelation regimen started early in life, and iron loss after single intramuscular or subcutaneous infusions of desferrioxamine is determined. Expand
Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical Progress
TLDR
Chelation therapy was associated with a significant reduction in liver iron concentration, and by the end of the trial the values for the two groups showed no overlap. Expand
Cardiac arrhythmias in thalassaemia major: evaluation of chelation treatment using ambulatory monitoring.
TLDR
This case report shows that the absence of clinical findings within five years does not preclude the later development of significant radiation-induced heart disease. Expand
IMPROVEMENT IN IRON STATUS AND LIVER FUNCTION IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD WITH LONG-TERM SUBCUTANEOUS DESFERRIOXAMINE
TLDR
These studies show that body-iron stores can be substantially reduced, to normal or near normal levels, by long-term subcutaneous desferrioxamine in patients with transfusional iron overload despite the need for continued blood-transfusion. Expand
Reassessment of the use of desferrioxamine B in iron overload.
TLDR
Constant exposure of the labile iron pool to a chelating agent markedly enhances net iron excretion in splenectomized transfusion-dependent patients. Expand
SUBCUTANEOUS INFUSION AND INTRAMUSCULAR INJECTION OF DESFERRIOXAMINE IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD
TLDR
Continuous subcutaneous infusion of D.F. produces more iron excretion in patients with iron overload than intramuscular injection, and may prove a valuable means of preventing or treating iron overload in anaemic patients maintained on regular blood-transfusions. Expand
Chelating Agents in the Diagnosis and Treatment of Iron Overload in Thalassemia
  • R. Smith
  • Medicine
  • Annals of the New York Academy of Sciences
  • 1964
TLDR
An attempt is made to assess the practical value of DF and DTPA in iron overload, which have a high affinity for iron in vitro, and have been found to remove significant quantities of iron from patients with iron overload due to idiopathic hemochromatosis, refractory anemia and thalassemia. Expand
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
TLDR
Efficient methods of analysis of randomized clinical trials in which the authors wish to compare the duration of survival among different groups of patients are described. Expand
Echocardiographic abnormalities in patients with transfusion-dependent anemia and secondary myocardial iron deposition.
TLDR
Echocardiography provides a simple noninvasive means for assessing changes in cardiac structure and function that should prove useful in the serial evaluation of patients who are at risk for the development of myocardial iron deposition. Expand
...
1
2
...